Novel CV Risk Reduction Therapies in TD2 and CVD: Consensus Decision Pathways (ACC, 2019) - Medscape

Novel CV Risk Reduction Therapies in TD2 and CVD: Consensus Decision Pathways (ACC, 2019)  Medscape

2018 expert consensus decision pathways by the American College of Cardiology for novel therapies for cardiovascular risk reduction in individuals with type 2 ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more